• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New paradigms in purinergic receptor ligand discovery
Neuropharmacology. 2023 Mar 13:109503. doi: 10.1016/j.neuropharm.2023.109503. Online ahead of print.ABSTRACTThe discovery and clinical implementation of modulators of adenosine, P2Y and P2X receptors have progressed dramatically in ∼50 years since Burnstock's definition of purinergic signaling. Although most clinical trials of selective ligands (agonists and antagonists) of these nineteen receptors failed, there is a renewed impetus to redirect efforts to new disease conditions and the discovery of more selective or targeted compounds with potentially reduced side effects, such as biased GPCR agonists. The elucidation of...
Source: Neuropharmacology - March 15, 2023 Category: Drugs & Pharmacology Authors: Kenneth A Jacobson Balaram Pradhan Zhiwei Wen Asmita Pramanik Source Type: research

Prolyl hydroxylase domain inhibitors: can multiple mechanisms be an opportunity for ischemic stroke?
Abstract Stroke and cerebrovascular disease are now the fifth most common cause of death behind other diseases such as heart, cancer and respiratory disease and accounts for approximately 40-50 fatalities per 100,000 people each year in the United States. Currently the only therapy for acute stroke, is intravenous administration of tissue plasminogen activator which was approved in 1996 by the FDA. Surprisingly no new treatments have come on the market since, although endovascular mechanical thrombectomy is showing promising results in trials. Recently focus has shifted towards a preventative therapy rather than t...
Source: Neuropharmacology - December 19, 2018 Category: Drugs & Pharmacology Authors: Lanigan SM, O'Connor JJ Tags: Neuropharmacology Source Type: research

The use of stimulant medications for non-core aspects of ADHD and in other disorders.
Abstract Psychostimulants play a central role in the management of ADHD. Here we review the evidence pertaining to the use of methylphenidate, dexamphetamine and related amphetamine salts, the prodrug lisdexamfetamine and modafinil for the management of comorbid ADHD and non-ADHD indications. There is a growing consensus that stimulant medications are helpful at improving the emotional dysregulation and lability, and oppositional and conduct symptoms that are often associated with ADHD. There is some evidence that psychostimulants may improve outcomes in those with treatment resistant depression, reduce negative s...
Source: Neuropharmacology - June 18, 2014 Category: Drugs & Pharmacology Authors: Sinita E, Coghill D Tags: Neuropharmacology Source Type: research